![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dichloroethane | decreases expression | ISO | RGD:1331928 | 6480464 | ethylene dichloride results in decreased expression of LPHN2 mRNA | CTD | PMID:28960355 | 17beta-estradiol | multiple interactions | ISO | RGD:732054 | 6480464 | [Estradiol co-treated with Progesterone] results in decreased expression of ADGRL2 mRNA | CTD | PMID:20660070 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:732054 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ADGRL2 mRNA | CTD | PMID:20106945, PMID:21632981 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:1331928 | 6480464 | [TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ADGRL2 mRNA | CTD | PMID:25975270 | 2,4-diaminotoluene | decreases expression | ISO | RGD:1331928 | 6480464 | 2, 4-diaminotoluene results in decreased expression of ADGRL2 mRNA | CTD | PMID:20713471 | 2,4-dinitrotoluene | affects expression | EXP | | 6480464 | 2, 4-dinitrotoluene affects the expression of ADGRL2 mRNA | CTD | PMID:21346803 | 3,4-methylenedioxymethamphetamine | decreases expression | EXP | | 6480464 | N-Methyl-3, 4-methylenedioxyamphetamine results in decreased expression of ADGRL2 mRNA | CTD | PMID:30071829 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:732054 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADGRL2 mRNA | CTD | PMID:28628672 | 3H-1,2-dithiole-3-thione | decreases expression | EXP | | 6480464 | 1, 2-dithiol-3-thione results in decreased expression of ADGRL2 mRNA | CTD | PMID:19162173 | 4,4'-diaminodiphenylmethane | decreases expression | EXP | | 6480464 | 4, 4'-diaminodiphenylmethane results in decreased expression of ADGRL2 mRNA | CTD | PMID:30723492 | 4-hydroxyphenyl retinamide | increases expression | ISO | RGD:1331928 | 6480464 | Fenretinide results in increased expression of ADGRL2 mRNA | CTD | PMID:28973697 | 5-fluorouracil | affects response to substance | ISO | RGD:732054 | 6480464 | ADGRL2 protein affects the susceptibility to Fluorouracil | CTD | PMID:16217747 | 6-propyl-2-thiouracil | increases expression | EXP | | 6480464 | Propylthiouracil results in increased expression of ADGRL2 mRNA | CTD | PMID:24780913, PMID:25825206 | acetamide | decreases expression | EXP | | 6480464 | acetamide results in decreased expression of ADGRL2 mRNA | CTD | PMID:31881176 | aflatoxin B1 | decreases expression | ISO | RGD:1331928 | 6480464 | Aflatoxin B1 results in decreased expression of ADGRL2 mRNA | CTD | PMID:19770486 | aflatoxin B1 | increases methylation | ISO | RGD:732054 | 6480464 | Aflatoxin B1 results in increased methylation of ADGRL2 intron | CTD | PMID:30157460 | arsenite(3-) | decreases expression | ISO | RGD:732054 | 6480464 | arsenite results in decreased expression of ADGRL2 mRNA | CTD | PMID:23974009 | benzo[a]pyrene | decreases expression | ISO | RGD:1331928 | 6480464 | Benzoapyrene results in decreased expression of ADGRL2 mRNA | CTD | PMID:19770486 | benzo[a]pyrene | decreases methylation | ISO | RGD:732054 | 6480464 | Benzoapyrene results in decreased methylation of LPHN2 5' UTR | CTD | PMID:27901495 | benzo[a]pyrene | increases methylation | ISO | RGD:732054 | 6480464 | Benzoapyrene results in increased methylation of LPHN2 promoter | CTD | PMID:27901495 | benzo[a]pyrene | increases expression | ISO | RGD:1331928 | 6480464 | Benzoapyrene results in increased expression of ADGRL2 mRNA | CTD | PMID:22610609 | benzo[b]fluoranthene | increases expression | ISO | RGD:1331928 | 6480464 | benzobfluoranthene results in increased expression of ADGRL2 mRNA | CTD | PMID:26377693 | beta-naphthoflavone | multiple interactions | ISO | RGD:1331928 | 6480464 | AHR protein affects the reaction [beta-Naphthoflavone results in decreased expression of ADGRL2 mRNA] | CTD | PMID:22234961 | beta-naphthoflavone | decreases expression | ISO | RGD:1331928 | 6480464 | beta-Naphthoflavone results in decreased expression of ADGRL2 mRNA | CTD | PMID:22234961 | bis(2-chloroethyl) sulfide | affects expression | EXP | | 6480464 | Mustard Gas affects the expression of ADGRL2 mRNA | CTD | PMID:15651846 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of ADGRL2 mRNA | CTD | PMID:12075121, PMID:30816183 | bisphenol A | increases expression | ISO | RGD:732054 | 6480464 | bisphenol A results in increased expression of ADGRL2 mRNA | CTD | PMID:29275510 | bisphenol A | decreases methylation | ISO | RGD:1331928 | 6480464 | bisphenol A results in decreased methylation of ADGRL2 promoter | CTD | PMID:27312807 | bisphenol A | multiple interactions | ISO | RGD:732054 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADGRL2 mRNA | CTD | PMID:28628672 | bisphenol A | affects expression | EXP | | 6480464 | bisphenol A affects the expression of ADGRL2 mRNA | CTD | PMID:25181051 | butanal | decreases expression | ISO | RGD:732054 | 6480464 | butyraldehyde results in decreased expression of ADGRL2 mRNA | CTD | PMID:26079696 | calcium atom | multiple interactions | EXP | | 6480464 | [alpha-latrotoxin binds to ADGRL2 protein] which results in increased uptake of Calcium, [black widow spider venom binds to ADGRL2 protein] which results in increased uptake of Calcium | CTD | PMID:10026162 | calcium(0) | multiple interactions | EXP | | 6480464 | [alpha-latrotoxin binds to ADGRL2 protein] which results in increased uptake of Calcium, [black widow spider venom binds to ADGRL2 protein] which results in increased uptake of Calcium | CTD | PMID:10026162 | choline | multiple interactions | ISO | RGD:1331928 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ADGRL2 gene, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of and results in decreased expression of ADGRL2 | CTD | PMID:20938992 | chromium atom | decreases expression | ISO | RGD:732054 | 6480464 | Chromium results in decreased expression of ADGRL2 mRNA | CTD | PMID:21437242 | copper atom | multiple interactions | ISO | RGD:1331928 | 6480464 | [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ADGRL2 mRNA | CTD | PMID:15467011 | copper(0) | multiple interactions | ISO | RGD:1331928 | 6480464 | [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ADGRL2 mRNA | CTD | PMID:15467011 | cyclosporin A | decreases expression | ISO | RGD:732054 | 6480464 | Cyclosporine results in decreased expression of ADGRL2 mRNA | CTD | PMID:20106945, PMID:25562108 | dexamethasone | decreases expression | EXP | | 6480464 | Dexamethasone results in decreased expression of ADGRL2 mRNA | CTD | PMID:14618091 | dexamethasone | multiple interactions | ISO | RGD:732054 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADGRL2 mRNA | CTD | PMID:28628672 | dibutyl phthalate | increases expression | EXP | | 6480464 | Dibutyl Phthalate results in increased expression of ADGRL2 mRNA | CTD | PMID:21266533 | dibutyl phthalate | increases expression | ISO | RGD:1331928 | 6480464 | Dibutyl Phthalate results in increased expression of ADGRL2 mRNA | CTD | PMID:17361019, PMID:21266533 | dorsomorphin | multiple interactions | ISO | RGD:732054 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of ADGRL2 mRNA | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | RGD:732054 | 6480464 | Doxorubicin results in decreased expression of ADGRL2 mRNA | CTD | PMID:29803840 | endosulfan | decreases expression | EXP | | 6480464 | Endosulfan results in decreased expression of ADGRL2 mRNA | CTD | PMID:29391264 | ethanol | increases expression | EXP | | 6480464 | Ethanol results in increased expression of ADGRL2 mRNA | CTD | PMID:15353170 | ethanol | increases expression | ISO | RGD:1331928 | 6480464 | Ethanol results in increased expression of ADGRL2 mRNA | CTD | PMID:30319688 | flusilazole | affects expression | ISO | RGD:1331928 | 6480464 | flusilazole affects the expression of ADGRL2 mRNA | CTD | PMID:21195148 | flutamide | decreases expression | EXP | | 6480464 | Flutamide results in decreased expression of ADGRL2 mRNA | CTD | PMID:24136188, PMID:24793618 | folic acid | multiple interactions | ISO | RGD:1331928 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ADGRL2 gene, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of and results in decreased expression of ADGRL2 | CTD | PMID:20938992 | fonofos | increases methylation | ISO | RGD:732054 | 6480464 | Fonofos results in increased methylation of ADGRL2 promoter | CTD | PMID:22847954 | furan | increases methylation | EXP | | 6480464 | furan results in increased methylation of ADGRL2 gene | CTD | PMID:22079235 | hexaconazole | affects expression | ISO | RGD:1331928 | 6480464 | hexaconazole affects the expression of ADGRL2 mRNA | CTD | PMID:21195148 | indometacin | multiple interactions | ISO | RGD:732054 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADGRL2 mRNA | CTD | PMID:28628672 | L-methionine | multiple interactions | ISO | RGD:1331928 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ADGRL2 gene, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of and results in decreased expression of ADGRL2 | CTD | PMID:20938992 | methapyrilene | decreases expression | EXP | | 6480464 | Methapyrilene results in decreased expression of ADGRL2 mRNA | CTD | PMID:30467583 | methotrexate | affects response to substance | ISO | RGD:732054 | 6480464 | ADGRL2 protein affects the susceptibility to Methotrexate | CTD | PMID:16217747 | nefazodone | decreases expression | EXP | | 6480464 | nefazodone results in decreased expression of ADGRL2 mRNA | CTD | PMID:24136188 | nimesulide | decreases expression | EXP | | 6480464 | nimesulide results in decreased expression of ADGRL2 mRNA | CTD | PMID:24136188 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of ADGRL2 mRNA | CTD | PMID:25729387 | paracetamol | affects expression | ISO | RGD:1331928 | 6480464 | Acetaminophen affects the expression of ADGRL2 mRNA | CTD | PMID:17562736 | paracetamol | decreases expression | ISO | RGD:732054 | 6480464 | Acetaminophen results in decreased expression of ADGRL2 mRNA | CTD | PMID:21420995 | parathion | increases methylation | ISO | RGD:732054 | 6480464 | Parathion results in increased methylation of ADGRL2 promoter | CTD | PMID:22847954 | pirinixic acid | multiple interactions | ISO | RGD:1331928 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of ADGRL2 mRNA | CTD | PMID:19710929 | pirinixic acid | decreases expression | EXP | | 6480464 | pirinixic acid results in decreased expression of ADGRL2 mRNA | CTD | PMID:19162173 | potassium chromate | decreases expression | ISO | RGD:732054 | 6480464 | potassium chromateVI results in decreased expression of ADGRL2 mRNA | CTD | PMID:22714537 | progesterone | multiple interactions | ISO | RGD:732054 | 6480464 | [Estradiol co-treated with Progesterone] results in decreased expression of ADGRL2 mRNA | CTD | PMID:20660070 | quercetin | decreases expression | ISO | RGD:732054 | 6480464 | Quercetin results in decreased expression of ADGRL2 mRNA | CTD | PMID:21632981 | SB 431542 | multiple interactions | ISO | RGD:732054 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of ADGRL2 mRNA | CTD | PMID:27188386 | sunitinib | increases expression | ISO | RGD:732054 | 6480464 | Sunitinib results in increased expression of ADGRL2 mRNA | CTD | PMID:31533062 | terbufos | increases methylation | ISO | RGD:732054 | 6480464 | terbufos results in increased methylation of ADGRL2 promoter | CTD | PMID:22847954 | titanium dioxide | decreases expression | EXP | | 6480464 | titanium dioxide results in decreased expression of ADGRL2 mRNA | CTD | PMID:30012374 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of ADGRL2 mRNA | CTD | PMID:25729387 | topotecan | increases expression | EXP | | 6480464 | Topotecan results in increased expression of ADGRL2 mRNA | CTD | PMID:25729387 | triadimefon | affects expression | ISO | RGD:1331928 | 6480464 | triadimefon affects the expression of ADGRL2 mRNA | CTD | PMID:21195148 | valproic acid | increases expression | ISO | RGD:732054 | 6480464 | Valproic Acid results in increased expression of ADGRL2 mRNA | CTD | PMID:24383497 more ... | valproic acid | multiple interactions | ISO | RGD:732054 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of ADGRL2 mRNA | CTD | PMID:27188386 | vorinostat | increases expression | ISO | RGD:732054 | 6480464 | vorinostat results in increased expression of ADGRL2 mRNA | CTD | PMID:27188386 | |